Ethics Statement
The study was approved by the Ethics Committee of National Institution for Viral Disease Control and Prevention, China CDC (Ethical approval No. IVDC2020-021).
References
1. Li Y, Wang X, Shen XR, et al. A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity. Emerg Microbes Infect. 2022;11(1):902-913.
2. Lu Z, Laing ED, Pena DaMata J, et al. Durability of SARS-CoV-2-specific T-cell responses at 12 months postinfection. J Infect Dis. 2021;224(12):2010-2019.
3. Zhang J, Lin H, Ye B, et al. One-year sustained cellular and humoral immunities of COVID-19 convalescents. Clin Infect Dis.2021;75(1):e1072-e1081.
4. Yang Y, Yang M, Peng Y, et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat Microbiol. 2022;7(3):423-433.
5. Alter G, Yu J, Liu J, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature.2021;596(7871):268-272.
6. Dai L, Gao L, Tao L, et al. Efficacy and safety of the RBD-dimer-based COVID-19 vaccine ZF2001 in adults. N Engl J Med.2022;386(22):2097-2111.
7. Li Z, Xiang T, Liang B, et al. Characterization of SARS-CoV-2-specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting. Front Immunol. 2021;12:802858.
8. Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.Nature. 2021;595(7868):572-577.
9. Wang X, Zhao X, Song J, et al. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerg Microbes Infect.2022;11(1):477-481.
10. Ju B, Fan Q, Wang M, et al. Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections. Nat Commun. 2022;13(1):7120.
11. Fan Q, Shi J, Yang Y, et al. Clinical characteristics and immune profile alterations in vaccinated individuals with breakthrough Delta SARS-CoV-2 infections. Nat Commun. 2022;13(1):3979.
12. Liu WJ, Xu J. The arams race in the war between virus and host: implications for anti-infection immunity. Infectious Diseases & Immunity. 2022;2(3):129-131.
13. Dyer O. Covid-19: Omicron is causing more infections but fewer hospital admissions than Delta, South African data show. Bmj.2021;375:n3104.
14. Saxena SK, Kumar S, Ansari S, et al. Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus-2 Omicron variant of concern. J Med Virol.2022;94(5):2160-2166.
15. Saxena SK, Kumar S, Ansari S, et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94(4):1738-1744.
16. He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant: characteristics and prevention. MedComm (2020).2021;2(4):838-845.
17. Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear.Bmj. 2021;375:n2943.
18. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature.2022;602(7898):657-663.
19. Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature.2022;602(7898):676-681.
20. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature.2022;602(7898):671-675.
21. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N Engl J Med.2022;386(6):599-601.
22. Zhao Y, Zhao X, Zhang R, et al. Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: a preliminary observation. Lancet Reg Health West Pac.2022;21:100440.
23. Zhao X, Li D, Ruan W, et al. Effects of a prolonged booster interval on neutralization of Omicron variant. N Engl J Med.2022;386(9):894-896.
24. De Marco L, D’Orso S, Pirronello M, et al. Assessment of T-cell reactivity to the SARS-CoV-2 Omicron variant by immunized individuals.JAMA Netw Open. 2022;5(4):e2210871.
25. Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat Med.2022;28(3):472-476.
26. Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature.2022;603(7901):493-496.
27. Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022;185(5):847-859.e811.
28. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022;603(7901):488-492.
29. Xu Z, Liu K, Gao GF. Omicron variant of SARS-CoV-2 imposes a new challenge for the global public health. Biosaf Health.2022;4(3):147-149.
30. Liu WJ, Liu S. A tale of two cities: from influenza HxNy to SARS-CoV-z. China CDC Wkly. 2021;3(49):1052-1056.
31. Xu K, Fan C, Han Y, Dai L, Gao GF. Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021;34(12):595-607. Int Immunol. 2022.
32. Fu Y, Zhao J, Wei X, et al. Effectiveness and cost-effectiveness of inactivated vaccine to address COVID-19 pandemic in China: evidence from randomized control trials and real-world studies. Front Public Health. 2022;10:917732.
33. Glück V, Grobecker S, Köstler J, et al. Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel.Infection. 2022;50(2):439-446.
34. Guo L, Wang G, Wang Y, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe.2022;3(5):e348-e356.
35. Yan LN, Liu PP, Li XG, et al. Neutralizing antibodies and cellular immune responses against SARS-CoV-2 sustained one and a half years after natural infection. Front Microbiol. 2021;12:803031.
36. Matula Z, Gönczi M, Bekő G, et al. Antibody and T cell responses against SARS-CoV-2 elicited by the third dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines using a homologous or heterologous booster vaccination strategy. Vaccines (Basel).2022;10(4):539.
37. Vályi-Nagy I, Matula Z, Gönczi M, et al. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.Geroscience. 2021;43(5):2321-2331.
38. Li J, Wu J, Long Q, et al. Comprehensive humoral and cellular immune responses to SARS-CoV-2 variants in diverse Chinese population.Research (Wash D C). 2022;2022:9873831.
39. Cheng ZJ, Huang H, Zheng P, et al. Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization.Allergy. 2022;77(8):2404-2414.
40. Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med.2021;13(577):eabd2223.
41. Patil HP, Rane PS, Shrivastava S, et al. Antibody (IgA, IgG, and IgG subtype) responses to SARS-CoV-2 in severe and nonsevere COVID-19 patients. Viral Immunol. 2021;34(3):201-209.
42. Havervall S, Ng H, Jernbom Falk A, et al. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. J Intern Med.2022;291(1):72-80.
43. Mudd PA, Minervina AA, Pogorelyy MV, et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell. 2022;185(4):603-613.e615.
44. Prendecki M, Clarke C, Edwards H, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis. 2021;80(10):1322-1329.
45. Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci Immunol.2021;6(59):eabj1750.
46. Lin H, Liu X, Sun H, et al. Sustained abnormality with recovery of COVID-19 convalescents: a 2-year follow-up study. Sci Bull (Beijing). 2022;67(15):1556-1561.
47. Bayarri-Olmos R, Idorn M, Rosbjerg A, et al. SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain. J Immunol. 2021;207(3):878-887.
48. Pourakbari B, Mirbeyk M, Mahmoudi S, et al. Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in Iran. J Med Virol. 2022;94(12):5669-5677.